Universal Ibogaine logo

Universal Ibogaine(OTC) IBOGF

Market Cap$55.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year-99%
1 Month-100%
$0.00
-50.00%
-0.00Today
Universal Ibogaine last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-02
Universal Ibogaine stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-25
1 month-99.52%USD 0.022026-09-02
3 month-99.62%USD 0.032026-07-02
Year to date-96.97%USD 0.002025-12-31
1 year-99.06%USD 0.012025-10-02
3 year-98.65%USD 0.012023-09-29
Since inception-99.87%USD 0.082022-03-01

Universal Ibogaine Financials at a Glance

Market Cap

$55.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$1.54M

Net Income (TTM)

-CA$1.65M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.00

Volume

36,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.35

Estimated Earnings Date

Jan 9, 2026

IBOGF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Universal Ibogaine

Universal Ibogaine Inc. is a life sciences company dedicated to developing and operating addiction treatment centers across Canada. The organization is also preparing to initiate clinical trials to explore the therapeutic potential of ibogaine for addiction treatment.

Products and Services
  • Development of addiction treatment centers in Canada
  • Research on ibogaine's therapeutic applications
  • Clinical trials aimed at addiction recovery
Growth Outlook
  • Expansion of treatment centers aligns with increasing demand for addiction services
  • Clinical trials may position the company as a leader in innovative addiction therapies
  • Potential partnerships with healthcare providers could enhance service delivery
Financial Highlights
  • Recent quarterly revenue of 700,918 CAD shows significant growth
  • Trailing twelve months (TTM) revenue of 1,000,000 CAD indicates upward trend
  • Operating income margin improved to 36.35% in the latest quarter
Universal Ibogaine Inc. operates in the biotechnology sector, focusing on innovative solutions for addiction treatment. The company is strategically positioned to capitalize on the growing need for effective addiction recovery services. With a recent quarterly revenue of 700,918 CAD, the organization demonstrates a strong upward trajectory, reflecting its commitment to addressing addiction through research and clinical applications. The TTM revenue of 1,000,000 CAD further underscores the company's potential for growth. The operating income margin of 36.35% in the latest quarter indicates improved efficiency and profitability, suggesting that the company is effectively managing its operational costs while expanding its services. As the demand for addiction treatment continues to rise, Universal Ibogaine Inc. is poised to play a significant role in the healthcare landscape, making it an intriguing option for investors interested in the biotechnology sector.
AI Generated • Sep 20, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

CEO

Nicholas Peter Karos

Website

www.universalibogaine.com

Headquarters

Calgary, AB T2P 3P2, CA

IBOGF Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

23.67%

Net Income Margin

-88.01%

Return on Equity

-149.60%

Return on Capital

8.75%

Return on Assets

-45.46%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$55.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

274.83M

Volume

36.00K

Avg. Volume

245.00K

Financials (TTM)

Gross Profit

CA$1.18M

Operating Income

CA$189.39K

EBITDA

-CA$1.20M

Operating Cash Flow

-CA$964.68K

Capital Expenditure

-CA$253.52K

Free Cash Flow

-CA$1.22M

Cash & ST Invst.

CA$127.75K

Total Debt

CA$2.57M

Universal Ibogaine Performance Analysis

Universal Ibogaine annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-07-31CAD 843,715N/A
20232023-07-31CAD 767,615-9.0%
20242024-07-31CAD 1,715,149123.4%
Universal Ibogaine sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-01-31N/A
Q32023-04-30937.9%
Q22025-01-31N/A
Q32025-04-3088.6%
Universal Ibogaine annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-07-31CAD -0.04N/A
20232023-07-31CAD -0.01-79.1%
20242024-07-31CAD -0.01-30.1%
Universal Ibogaine sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-01-316.8%
Q32023-04-3039.0%
Q22025-01-31N/A
Q32025-04-3080.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

CA$700.92K

N/A

Gross Profit

CA$700.92K

N/A

Gross Margin

100.00%

N/A

Market Cap

$55.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.86K

N/A

Employees

7

N/A

Net Income

-CA$66.20K

+92.1%

EBITDA

CA$52.89K

+107.3%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

CA$127.75K

-81.8%

Total Debt

CA$2.57M

+11.9%

Accounts Receivable

CA$608.26K

+421.8%

Inventory

CA$0.00

N/A

Long Term Debt

CA$1.72M

+130.2%

Short Term Debt

CA$848.92K

-45.3%

Return on Assets

-45.46%

N/A

Return on Invested Capital

15.69%

N/A

Free Cash Flow

-CA$110.37K

+81.4%

Operating Cash Flow

-CA$110.37K

+75.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VGLSSB Technology Holdings Inc.
$0.22+0.00%
APLIFAppili Therapeutics Inc
$0.01+0.00%
AGNPFGrey Matters Health Inc.
$0.25+0.32%
HESGHealth Sciences Group, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NKENike
$33.87-3.64%
NVDANvidia
$233.95+1.34%
SPCXSpace Exploration Technologies
$158.96+7.36%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$29.71-6.46%

Questions About IBOGF

What is the current price of Universal Ibogaine?

Universal Ibogaine is trading at $0.00 per share.

What is the 52-week range for Universal Ibogaine?

Over the past 52 weeks, Universal Ibogaine has traded between $0.00 and $0.35.

How much debt does Universal Ibogaine have?

As of the most recent reporting period, Universal Ibogaine reported total debt of CA$1.86M.

How much cash does Universal Ibogaine have on hand?

Universal Ibogaine reported CA$92.48K in cash and cash equivalents in its most recent financial results.

What is Universal Ibogaine’s dividend yield?

Universal Ibogaine does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services